Abstract

Aim of the study: The study aims to find the effect of low level laser therapy on the diabetic peripheral neuropathy patients. To evaluate the effect of low level laser therapy on the diabetic peripheral neuropathy patients. Background of the study: Diabetic peripheral neuropathy is the nerve damage caused by chronically high blood sugar and it leads to numbness, loss of sensation and sometimes pain in the feet,legs or hands. Diabetic Peripheral Neuropathy is a result of injury to the vasa nervosum, axons and atrophy of the axons leading to tissue damage. Methodology: Thiswas an experimental study of comparative of pre and post type. 14 patients are selectedselected from the A.C.S College and hospital and they divided into two groups. Group A received low level laser therapy Group B received interferential therapy. Pre and post test measurements taken using Pressure - Mono Filament Method, Vibration – Tuning Fork (128 Hz), Mc GillPain.

• 1.   Tripathi BK, Srivastava AK. Diabetes mellitus: complications and therapeutics. Med Sci Monit. 2006;12(7):RA130–47.
• 2.   Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus–present and future perspectives. Nat Rev Endocrinol. 2011;8(4):228–36.
• 3.   Zhang PH, Chen ZW, Lv D, et al. Increased risk of cancer in patients with type 2 diabetes mellitus: a retrospective cohort study in China. BMC Public Health. 2012;12:567.
• 4.   Gastaldelli A. Role of beta-cell dysfunction, ectopic fat accumulation and insulin resistance in the pathogenesis of type 2 diabetes mellitus. Diabetes Res Clin Pract. 2011;93(1):S60–65.
• 5.   Ismail-Beigi F. Pathogenesis and glycemic management of type 2 diabetes mellitus: a physiological approach. Arch Iran Med. 2012; 15(4):239–46.
• 6.   Boulton AJM, Amstrong WD, Scarpello JHB, Ward JD.The natural history of painful diabetic neuropathy : A 4 years study. Postgraduate Med J. 1983;59:556–9.
• 7.   Thomes PK. Classification, differential diagnosis andstaging of diabetic peripheral neurophathy. Diabetes. 1997;46(suppl-2):54S–57S.
• 8.   Feldman EL, Stevens MJ, Greene DA. Pathogenesis of diabetic neuropathy. Clin Neuro Sci. 1997;4: 365–70.
• 9.   Hile C, Veves A. Diabetic neuropathy and microcirculation. Curr Diab Rep. 2003;3(6):446–51.
• 10.   Andrew J.M. Boulton, MD, DSc (Hon), FRCP: Management of Diabetic Peripheral Neuropathy. Clinical Diabetes. 2005;23:9–15.
• 11.   Boulton AJ, Malik RA, Arezzo JC. Diabetic somatic neuropathies. Diabetes Care. 2004;27:1458–86.
• 12.   Galer BS, Gianas A, Jensen MP. Painful diabeticpolyneuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Pract. 2000;47:123–28.
• 13.   Gordois A, Scuffham P, Shearer A, Oglesby A, Tobian JA. The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care 2003;26:1790–95.